Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
extension tags : Disease save search
Bipolar Disorder Landscape Report with DLI's Clinical Trial Assessment, Product Portfolio Extension, and Post Launch Services | Disease Landscape Insights
Published: 2023-10-09 (Crawled : 14:00) - prnewswire.com
ALPMY | News | $9.5 -1.11% 1M
|
Manufacturing
|
| O: -0.04%
H: 0.77%
C: 0.7%
disease services report trial
Innovations in Tonsillitis Disease Landscape Report: DLI's Extensive Disease Insights, Unmet Needs Analysis, KOL Perspectives, Epidemiology Study, and Regulatory Consulting Services | Disease Landscape Insights
Published: 2023-10-03 (Crawled : 10:00) - prnewswire.com
QDEL | News M | $39.08 -0.1% -0.1% 890K
|
Health Technology
|
| O: -0.62%
H: 1.52%
C: 1.0%
disease services
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
disease series extension program therapeutics
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
Published: 2023-06-14 (Crawled : 11:00) - globenewswire.com
EGRX | $4.55 -1.3% -1.32% 280K
|
Health Technology
|
| O: 7.28%
H: 0.0%
C: -11.43%
cal02 fda disease pharmaceuticals designation extension fast track designation
New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.332 -4.93% -5.18% 550K
|
|
| O: 6.67%
H: 1.56%
C: 0.0%
au8 rescue-als disease extension als trial show
New Publication Further Validates SeptiCyte® RAPID for Disease Severity Assessment and Triaging in COVID-19 Patients with Extensive Lung Injury
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
EXPR | $0.7 0.0% 22K
|
Retail Trade
|
| O: 0.0%
H: 1.0%
C: -1.9%
covid-19 septicyte lung disease rapid publication
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Published: 2023-02-22 (Crawled : 22:00) - globenewswire.com
FOLD F | $10.83 2.07% 2.03% 3.7M
|
Health Technology
|
| O: 0.23%
H: 0.11%
C: -0.38%
disease extension therapeutics positive study
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Published: 2022-12-20 (Crawled : 12:20) - globenewswire.com
ALT | $7.48 8.25% 7.62% 2.3M
|
Commercial Services
|
| O: -4.19%
H: 21.16%
C: 21.06%
liver disease topline trial positive results
Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management
Published: 2022-09-01 (Crawled : 12:00) - prnewswire.com
ZCMD | $1.58 -18.56% -22.78% 780K
|
Commercial Services
|
| O: 0.85%
H: 0.85%
C: -2.12%
management disease extension
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
Published: 2022-05-09 (Crawled : 12:20) - biospace.com/
ATHA | $2.08 -2.35% -2.4% 130K
|
Health Technology
|
| O: -10.47%
H: 3.1%
C: -2.0%
ath-1017 ongoing pharma trials label disease alzheimer’s alzheimer's fosgonimeton
TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases
Published: 2022-03-08 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
treatment disease trex media
Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD) Conference
Published: 2021-11-10 (Crawled : 21:00) - biospace.com/
BIIB | $194.1 -0.14% -0.15% 1.1M
|
Health Technology
|
| O: 0.0%
H: 1.44%
C: -1.15%
disease alzheimer ema phase 2 clinical trials trials phase 2b trial conference alzheimer’s alzheimer's disease alzheimer's biomarkers lecanemab
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
Published: 2021-07-30 (Crawled : 17:00) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: -3.11%
H: 0.0%
C: 0.0%
disease treatment ongoing phase 1 positive cholesterol
AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
Published: 2021-07-27 (Crawled : 21:00) - biospace.com/
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: 0.14%
disease collaboration
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
Published: 2021-07-06 (Crawled : 12:00) - athira.com
ATHA | $2.08 -2.35% -2.4% 130K
|
Health Technology
|
| O: 1.15%
H: 5.59%
C: 4.17%
disease alzheimer clinical trials trial ath-1017 alzheimer’s alzheimer's disease alzheimer's
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s DiseaseStudy Extension allows for additional 26 weeks of treatment on ATH-1017
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ATHA | $2.08 -2.35% -2.4% 130K
|
Health Technology
|
| O: 1.15%
H: 5.59%
C: 4.17%
disease alzheimer treatment clinical trials trial ath-1017 alzheimer’s alzheimer's
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.